Disappointed by Q1 Performance, HBIO Says Genomics Solutions Finally on Track | GenomeWeb

Harvard Bioscience last week reported a slight year-over-year increase in revenues for the first quarter, and turned a small net loss into a small profit.

Total revenues for the quarter increased to $22.4 million, up 1 percent from $22.2 million during the same quarter last year. The company's net income was $200,000, or $.01 per share, compared to a net loss of $51,000 during Q1 of 2004.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.